Brief: Ascletis Pharma Expands Ritonavir Oral Tablet Production Capacity To 100 Mln Tablets
03/01/2022 24:05
Jan 3 (Reuters) - Ascletis Pharma Inc 1672.HK :
* EXPANSION OF PRODUCTION OF RITONAVIR ORAL TABLETS, ORAL
DIRECT-ACTING ANTIVIRAL RESEARCH AND DEVELOPMENT PIPELINE FOR
TREATMENT OF SARS-COV-2
* RITONAVIR ORAL TABLET ANNUAL PRODUCTION CAPACITY HAS BEEN
EXPANDED TO 100 MILLION TABLETS
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026